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Abstract
Purpose: To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with
metastatsic CRC (mCRC).
Patients and Methods: Chemotherapy-naïve patients with mCRC, received bevacizumab (5 mg/kg every 2 weeks d1),
oxaliplatin (85 mg/m2 on d1), leucovorin (200 mg/m2) on days 1 and 2 and 5-Fluorouracil (400 mg/m2 as i.v. bolus and 600
mg/m2 as 22 h i.v. continuous infusion on days 1 and 2) every 2 weeks.
Results: Fifty three patients (46 with a PS 0–1) were enrolled. Complete and partial response was achieved in eight
(15.1%) and 28 (52.8%) patients, respectively (ORR: 67.9%; 95% C.I.: 53.8%–92%); 11 (20.7%) patients had stable disease
and six (11.3%) progressive disease. With a median follow up period of 13.5 months, time to tumor progression was 11
months while the median survival has not yet been reached; the probability of 1-, 2- and 3- year survival was 79.8%, 63.8%
and 58.3%, respectively; Two patients relapsed during the follow up period. Eight (15%) patients underwent
metastasectomy with R0 resections. Grade 3–4 neutropenia occurred in 15.1% of patients and one (1.9%) of them
presented febrile neutropenia. Non-hematologic toxicity included grade 3 diarrhea (7.6%) and grade 2 and 3
neurotoxicity in 16.9 and 15.1% of patients, respectively. One (1.9%) patient presented pulmonary embolism and one
(1.9%) cardiac ischaemia. There was one (1.9%) sudden death after the first cycle.
Conclusion: The combination of FOLFOX4/bevacizumab appears to be highly effective, well tolerated and merits
further evaluation in patients with mCRC.
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Background
Colorectal cancer (CRC) is a major cause of cancer mor-
bidity and mortality worldwide [1] accounting for 8% of
all malignant tumors in adults [2]. Despite that macro-
scopically curative surgical resection is possible in 70–
80% of patients at diagnosis, almost half of them will
develop local or/and metastatic recurrence and will die of
the disease.
Although, historically, chemotherapy was used for pallia-
tion of symptoms, during the last few years the median
overall survival of patients with advanced CRC has been
substantially increased from 12 months to about 21–22
months when all of the available chemotherapeutic
agents are administered [3]. Therefore treatment of meta-
static colorectal cancer (mCRC) has changed considerably
in the recent years. Combinations of 5-fluorouracil/Leu-
covorin (5-FU/LV) containing both bolus (Roswell Park)
and infusional administration (De Gramont schedule)
combined with a second active drug, either irinotecan [4]
or oxaliplatin are accepted as the mainstay of first-line
treatment, while the choice of a particular drug to com-
bine with 5FU does not influence overall survival[5].
The advent of targeted therapy further expanded treat-
ment options for patients with mCRC. In particular, inhi-
bition of angiogenesis by blocking Vascular Endothelial
Growth Factor (VEGF) using the monoclonal antibody
bevacizumab led to further improvement in the outcome
of patients with mCRC. Indeed, randomized studies dem-
onstrated that the addition of bevacizumab to either 5FU/
LV [6-8], or to an Irinotecan-5FU/LV combination (IFL)
[9] as first-line treatment of mCRC was associated with
improved objective response rate, time to tumor progres-
sion and overall survival.
During the last years, the IFL regimen (weekly irinotecan
and IV push administration of 5FU and LV) no longer rep-
resents the gold standard of front line treatment of mCRC
and it was replaced by the combinations of irinotecan or
oxaliplatin with the infusional 5-FU regimens (FOLFIRI
and FOLFOX, respectively) [10,11]. A recent study
(E3200) [12] demonstrated that the addition of bevacizu-
mab improved the activity of second-line oxaliplatin-con-
taining combination in patients with mCRC. However in
this study the effect of the combination on survival and
response rate was modest, reflecting the more advanced
stage of the disease in such patients.
Since there was no information concerning the efficacy
and tolerance of the combination of FOLFOX4 plus beva-
cizumab as front line treatment of patients with mCRC,
the Gastrointestinal (GI) Working Group of the Hellenic
Oncology Research Group (HORG) decided to conduct
this multicenter phase II study.
Methods
Eligibility criteria
Chemotherapy naïve patients, aged ≥ 18 years with histo-
logically documented mCRC were enrolled; other eligibil-
ity criteria included: patients who had received prior
adjuvant 5-FU-based chemotherapy were eligible if they
had remained free of disease for at least 6 months after the
completion of adjuvant therapy; performance status
(ECOG) 0–2; at least one bidimensionally measurable
lesion of ≥ 2 cm; a life expectancy of at least 3 months;
adequate hematologic parameters (absolute neutrophil
count ≥ 1.5 × 109/L and platelets ≥ 100 × 109/L); creati-
nine and total bilirubin ≤ 1.25 times the upper limit of
normal; aspartate and alanine aminotransferases ≤ 3.0
times the upper limit of normal; absence of active infec-
tion or malnutrition (loss of more than 10% of body
weight); absence of a second primary tumor other than
non-melanoma skin cancer or in situ cervical carcinoma;
patients receiving palliative radiotherapy had to have
measurable metastatic disease outside the irradiation
fields.
Patients with operable metastatic disease, clinically signif-
icant cardiovascular disease or major surgery within one
month prior to study registration were excluded from the
study. Other exclusion criteria included: pregnancy or lac-
tation, regular use of aspirin (more than 325 mg per day)
or other nonsteroidal anti-inflammatory agents; preexist-
ing bleeding diatheses or coagulopathy or the need for
full-dose anticoagulation; history of deep vein thrombosis
within one year prior to registration; uncontrolled hyper-
tension; pre-treatment proteinuria grade 2 or more and
known central nervous system metastases. Patients with
chronic diarrhea, or prior irradiation affecting more than
30% of the active bone marrow were also excluded. The
study was approved by the Ethics and Scientific Commit-
tees of each participating center. All patients gave written
informed consent in order to participate in the study.
Chemotherapy
Bevacizumab (Avastin®; Roche, Bale, Suisse) was given
prior to chemotherapy at a dose of 5 mg/kg every 2 weeks,
as a 2-hours infusion intravenous (IV) during the first
cycle, as a 1-hour IV infusion during the second cycle and
as a 30 min IV infusion in the subsequent cycles; L-OHP
(Eloxatin®; Sanofi-Aventis, Collegeville, USA) was admin-
istered on day 1 at the dose of 85 mg/m2 as a 2-hours IV
infusion; LV was given at the dose of 200 mg/m2 as a 2-
hour IV infusion, followed by 5-FU 400 mg/m2 as IV
bolus, and then, 600 mg/m2 as a 22-hour continuous IV
infusion, on days 1 and 2. Routine antiemetic prophylaxis
with a 5-hydroxytryptamine-3-receptor antagonist was
used in both study groups. Treatment was administered
every 2 weeks until disease progression or unacceptable
toxicity, or until the patient declined further treatment.BMC Cancer 2007, 7:91 http://www.biomedcentral.com/1471-2407/7/91
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No maintenance therapy with Bevacizumab after chemo-
therapy discontinuation was planned.
Patients were assessed for toxicity before each cycle using
the National Cancer Institute Common Toxicity Criteria
[13]. Chemotherapy was delayed until recovery if neu-
trophils were less than 1.5 × 109/L or platelets less than
100 × 109/L or for significant persisting nonhematologic
toxicity. Doses of LOHP and 5-FU were reduced by 15%
in subsequent cycles in case of grade 4 neutropenia or
grade 3–4 thrombocytopenia lasting for more than 3 days
or in case of febrile neutropenia. No prophylactic admin-
istration of granulocyte colony-stimulating factor (G-CSF)
was allowed. G-CSF was used for the treatment of febrile
neutropenia. Doses of 5-FU was reduced by 15% in subse-
quent cycles in case of grade 2–4 diarrhea, stomatitis or
dermatitis. L-OHP dose was reduced by 15% in cases of
persistent (≥ 14 days) paresthesia or temporary (7 to 14
days) painful paresthesia or functional impairment. In
cases of persistent (≥ 14 days) painful paresthesia or func-
tional impairment, L-OHP was omitted in subsequent
cycles until recovery. Bevacizumab was permanently dis-
continued in patients developing gastrointestinal perfora-
tion, wound dehiscence requiring medical intervention,
serious bleeding, nephrotic syndrome, or hypertensive cri-
sis. Temporary discontinuation of Bevacizumab adminis-
tration was implemented in patients with evidence of
moderate to severe proteinuria and in patients with severe
hypertension that was not controlled with medical man-
agement. Doses of bevacizumab and chemotherapy were
recalculated if the patient's weight changed by more than
10 percent during the study.
Patients' evaluation
Pre-treatment evaluation included a detailed medical his-
tory and physical examination, a complete blood cell
count (CBC) with differential and platelet count, blood
chemistry, urine analysis, serum levels of carcinoembry-
onic antigen (CEA) and computed tomography scans
(CT) of the chest and abdomen. Pretreatment evaluation
had to be performed within 2 weeks prior to study entry.
During treatment, a CBC with differential and platelets
count was performed weekly and in case of grade 3–4 neu-
tropenia, thrombocytopenia or febrile neutropenia it was
performed daily until hematologic recovery. In addition,
patients were clinically assessed and blood chemistry and
urine analysis were performed before each treatment
cycle. Response to treatment was evaluated every 2
months (4 chemotherapy cycles) or sooner if clinically
indicated. After the treatment period the patients without
disease progression, were evaluated with clinical examina-
tion and CT scans every 2 months.
The Response Evaluation Criteria in Solid Tumors
(RECIST) were used to assess tumour responses [14].
Complete response was defined as disappearance of all
disease without the appearance of new lesions. Partial
response was defined as a reduction of at least 30% in the
sum of the products of the longest diameters of all meas-
urable lesions. Disease progression was defined as an
increase of at least 20% in measurable tumor or an une-
quivocal increase in the size of non-measurable lesions or
the appearance of new lesions. After partial response,
tumor measurements exceeding 20% of the maximal
extent of a previously observed reduction constituted pro-
gression. Patients who did not meet the definitions of
response or progression were classified as having stable
disease. All objective responses were confirmed by a fol-
low-up CT scan at least 4 weeks following documentation
of the response.
Statistical Considerations
The primary end point of the study was the tumor
response rate. The study followed the optimal Simon two-
step design. If a minimum objective response rate exceed-
ing 45% was observed in the first 16 patients, 35 addi-
tional patients had to be enrolled (α = 0.05, power 80%).
Secondary objectives were the tolerance of the regimen as
well as response duration, time to tumor progression and
overall survival time. The duration of response was
defined as the time from the first documentation of
response to disease progression. The time to tumor pro-
gression (TTP) was determined by the interval between
the initiation of treatment and the date of first documen-
tation of disease progression or the date of death from any
cause. Overall survival (OS) was defined as the time from
treatment initiation to death. The follow up time was
defined as the period from treatment initiation to the
study's cutoff date (for alive patients). TTP and OS were
estimated by the Kaplan-Meier method [15], and the con-
fidence intervals for response rates were calculated using
methods for exact binomial confidence intervals [16].
Results
Patients' characteristics
Between May 2004 and September 2005, 53 patients were
enrolled, at three institutions and all of them received at
least one cycle of chemotherapy. Most of the patients
(median age 65 years) were males (56.6%) with good per-
formance status (ECOG 0–1: 86.7%) (Table 1). Fourteen
(26.4%) patients were newly diagnosed with metastatic
disease whereas 39 patients (73.6%) had prior resection
of the primary tumor. Of the latter group 13 had prior
adjuvant chemotherapy and six (11.3%) had also received
radiation therapy. The median time elapsed between the
diagnosis of metastasis and study entry was 1 month
(range, 0–2.5 months), while the median time between
initial disease diagnosis and the first metastasis was 16.5
months (range, 7–68 months), for patients with initially
operable disease. Thirty-four (64%) patients presentedBMC Cancer 2007, 7:91 http://www.biomedcentral.com/1471-2407/7/91
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liver metastasis and the median number of metastatic sites
was 2/patient (range, 2–5). Overall, approximately 22.6%
of the patients were classified as high risk according to the
Kohne prognostic index [17].
Compliance with the treatment
Five hundred and thirty nine chemotherapy courses were
administered (median, 12 courses/patient; range, 2–20).
Fifty (9.3%) chemotherapy courses were delayed for a
median of 7 days (range, 1–10) due to hematological (n =
21; 3.9%), non-hematologic (n = 10; 1.8%) toxicity, and
for reasons unrelated to disease or treatment (n = 19;
3.6%). The median interval between cycles was 16 days
(range, 14–24). Dose reduction of cytotoxic agents was
required in 27 (5%) cycles because of hematologic (n =
11; 2.1%), and non-hematologic (n = 16; 2.9%) toxicity.
The delivered relative dose intensity was 92% and 94% of
the protocol planned doses for L-OHP and 5-FU/LV,
respectively. At the time of this analysis, 49 (92.4%)
patients have discontinued treatment for the following
reasons: progressive disease (n = 40 patients), unaccepta-
ble neurotoxicity (n = 6 patients), death without disease
progression (n = 3 patients).
Treatment efficacy
In an intention-to-treat-analysis eight (15.1%) patients
achieved a documented complete response (CR) and 28
(52.8%) a partial response (PR), for an overall response
rate (ORR) of 67.9% (95% C.I.: 53.8%–92%). All objec-
tive response were documented with a following CT scan
at least 4 weeks later. In addition, 11 (20.8%) patients had
stable disease (SD) and six (11.4%) progressive disease
(PD). The median response duration was 8 months
(range, 3–21.2) and the median time to initial documen-
tation of response was 2 months (range, 2–4). The
median TTP was 11 months (range, 0.6–28) (Figure 1).
After a median follow-up period of 20 months (range,
0.6–38), 33 (71.7%) patients were still alive. The median
overall survival time has not yet been reached (range 0.6–
38.0); the probability of 1-, 2- and 3- year's survival was
79.8%, 63.8%, and 58.3 respectively.
In eight (15.1%) patients with initially unresectable met-
astatic lesions in the liver (n = 6) or the lungs (n = 2), a
metastasectomy was eventually performed following the
study treatment. The administration of bevacizumab was
interrupted 4 weeks prior to planned surgery. R0 resection
could be achieved in all patients (Table 2) and all patients
were uneventfully recovered. Two of those patients have
relapsed 11 and 13 months post-metastasectomy; after a
median follow up of 10 months (range, 4–18 months), all
metastasectomized patients were alive at the time of anal-
ysis.
Toxicity
Neutropenia and neuropathy were the most common
toxic effects of the combination. (Table 3). Grade 3–4
neutropenia was observed in eight (15.1%) patients and
one (1.9%) of them developed febrile neutropenia requir-
ing hospitalization and treatment with IV antibiotics.
Grade 3 anemia and thrombocytopenia occurred in one
(1.9%) patient each. Grade 3 diarrhea developed in four
(7.6%) patients. Neurosensory toxicity was observed in 35
(66%) patients and reached grade 3 in eight (15.1%) of
them. Cold-induced dysesthesia was reported in 18
(33.9%) patients. Paresthesia without pain occurred in
nine (16.9%) patients. Cumulative paresthesia occurred
in eight (15.1%) patients but without functional impair-
ment. The estimated incidence of grade 2 and 3 neurotox-
icity, attributed to L-OHP exposure, was 9% and 32% after
6 cycles, respectively. Other grade 3 or 4 toxicities were
infrequent. One patient died of sudden death, because of
cardiac rhythm abnormalities, after the first chemother-
Table 1: Patients' characteristics
No of patients %
Number of patients enrolled 53
Age (years)
Median (range) 65 (18 – 78)
Sex
Male 30 56.6
Female 23 43.4
Performance status (WHO)
02 6 4 9
12 0 3 7 . 7
27 1 3 . 2
Tumor Origin
Colon 36 67.9
Rectum 17 32.1
Prior Treatment
Surgery 39 73.6
Adjuvant chemotherapy 13 24.5
Adjuvant radiotherapy 6 11.3
Abnormal ALP# level at baseline 21 39.6
Abnormal WBC^ level at baseline 10 18.9
Abnormal PLT* level at baseline 61 1 . 3
Kohne prognostic index
Low risk 11 20.7
Intermediate risk 30 56.6
High risk 12 22.6
Sites of disease
Local Abdominal Mass 11 20.7
Liver 34 64.2
Lung 18 34
Lymph Nodes 17 32
Number of metastatic sites
11 4 2 6 . 4
23 0 5 6 . 6
≥ 3 median 9 17
Median (range) 2 (1–5)
#ALP: Alkaline Phosphatase, ^WBC: White cells Blood Count, *PLT: 
PlateletsBMC Cancer 2007, 7:91 http://www.biomedcentral.com/1471-2407/7/91
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apy cycle. Another patient developed unstable angina pec-
toris without infraction which was attributed to 5-FU-
induced coronary angiospasm. A third patient presented
an episode of pulmonary embolism but he was recovered
uneventfully. Only one patient presented severe gastroin-
testinal blending from the primary tumor in the descend-
ing colon (Table 4). In total four treatment-related
admissions to the hospital were reported. The death rate
during the first 60 days of treatment was 3.8% (95% CI,
1.0%–5.3%).
Discussion
The present study reports the efficacy and safety results of
the bevacizumab-FOLFOX4 combination as first-line
treatment for patients with mCRC. Although bevacizu-
mab has been accepted by most clinicians as a component
of the first-line treatment of mCRC, there is insufficient
information concerning the outcome of patients using
this combination in the first line setting.
The current multicenter phase II trial demonstrated that
the three-drug combination of bevacizumab, L-OHP and
5-FU/LV produced a high response rate (67.9%) with a
median duration of response of 7 months and a median
TTP of 11 months. The projected probabilities of 1-
(79.8%), 2- (63.8%) and 3- (58.3 %) year survival rates
were very promising. In addition, eight (15.1%) patients
with prior unresectable liver or pulmonary metastatic
lesions underwent secondary metastasectomies and R0
resection was able to be performed in all of them. These
efficacy results are among the highest reported in the liter-
ature for any chemotherapy regimen in mCRC. It is note-
worthy that these results were obtained with acceptable
toxicity.
Although, the present study has the limitations of any
phase II study, the patient population was representative
Table 4: Bevacizumab possibly related adverse events
Grade
12 3 4
n % n%n%n%
Pulmonary embolism - - - - - - 1 1.9
Cardiac ischaemia - - - - 1 1.9 - -
Epistaxis 4 7.6 1 1.9
Gastrointestinal 
bleeding
- - --1 1 . 9 --
Hypertension 5 9.5 2 3.8 - - -
Proteinuria 7 13.2 4 7.6 - - - -
Table 2: Characteristics of patients who underwent secondary 
metastasectomy
Metastatic 
sites
Response TTP 
(months)
Relapse
Patient 1 Liver CR 12 No
Patient 2 Liver PR 13 Yes (Liver)
Patient 3 Lung PR 4 No
Patient 4 Liver PR 9 No
Patient 5 Liver CR 11 Yes (Lung)
Patient 6 Lung PR 18 No
Patient 7 Liver PR 7 No
Patient 8 Liver PR 14 No
Kaplan-Meier time to tumor progression (TTP) of patients  treated with FOLFOX/Bevacizumab Figure 1
Kaplan-Meier time to tumor progression (TTP) of patients 
treated with FOLFOX/Bevacizumab.
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Table 3: Worst toxicity grade by patient during all cycles of 
treatment with the FOLFOX/BEVACIZUMAB combination
Grade
12 3 4
n% n % n % n %
Neutropenia 4 7.5 10 18.9 6 11.3 2 3.8
Febrile neutropenia - - - - 1 1.9 - -
Anemia 39 73.6 5 9.4 1 1.9 - -
Thrombocytopenia 8 15.1 2 3.8 1 1.9 - -
Nausea 6 11.3 1 1.9 1 1.9 - -
Vomiting 4 7.5 2 3.8 - - - -
Diarrhea 10 18.9 7 13.2 4 7.6 - -
Mucocitis 3 5.7 - - - - - -
Constipation 9 17.0 3 5.7 - - - -
Neurotoxicity 18 33.9 9 16.9 8 15.1 - -
Alopecia 12 22.6 2 3.8 - - - -
Fatigue 13 24.5 6 11.3 - - - -BMC Cancer 2007, 7:91 http://www.biomedcentral.com/1471-2407/7/91
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for this particular disease; indeed, almost one quarter of
the patients were classified as high risk, and more than
half of them as intermediate risk according to the Kohne
score, indicating the poor prognosis of those patients.
It is well known that bevacizumab enhances the activity of
the co-administered chemotherapy regimens that have
been so far studied as first or second line treatment of
colorectal cancer [6,7,9,18-21]. This has been docu-
mented by prospective randomized studies in the first-
line setting, using either 5-FU/LV, or IFL regimen
[7,9,20,21]; in the second line-setting, it enhances the
activity of the FOLFOX4 regimen, in bevacizumab-naïve
patients according to the E3200 study [12]. In the latter
study, the effect on survival and objective response rate
was rather modest, reflecting the more advanced stage of
the disease in such patients. Thus, the observations
regarding efficacy and possibly toxicity are not readily
transferable when the same drug combination is used as
first line treatment. This clearly necessitated the study of
the same combination in the first line. In the same E3200
study, although the toxicity of the chemotherapy combi-
nation was not enhanced by the addition of bevacizumab,
four cases of bowel perforation were observed. Such con-
cerns further enhance the importance of a meticulous
analysis of the activity and the toxicity of the combination
in the first line setting. A recent preliminary report of a
randomized phase II trial suggested that the addition of
bevacizumab improves the response rate, time to treat-
ment failure and median overall survival when it was
added to standard L-OHP-based chemotherapy [22]. The
only phase III (NO 16966) reported until now, demon-
strated a relatively small but statistically significant (1.5
months, p = 0.0023) improvement for progression free
survival when bevacizumab was added to L-OHP based
regimens XELOX or FOLFOX4, although that survival data
were missing [23].
Since the benefit of bevacizumab seems to be independ-
ent of the combination used as front line treatment, it is
not clear whether the clinical benefit of bevacizumab is
specific to the combination of irinotecan and 5-FU/LV
used in the phase III study. In fact, combining FOLFOX-4
with bevacizumab as second line treatment and at higher
doses than those used in the pivotal study, increased the
response and the overall survival rates albeit to a smaller
extend. In addition, non-randomized studies suggest an
advantage to combining Bevacizumab with oxaliplatin
plus bolus 5FU in the first line setting [22].
In summary, our results indicate that the combination of
FOLFOX and bevacizumab is feasible and highly effective,
and merits further evaluation in a phase III trial.
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